THU0063 Autoantibodies to human myc far upstream element-binding protein in patients with rheumatoid arthritis. (1st June 2001)

• Record Type: Journal Article
• Authors: Nojima, T; Suwa, A; Hirakata, M; Ikeda, Y; Mimori, T
• Is Part Of: Annals of the rheumatic diseases. Volume 60(2001)Supplement 1
• Page Start: A358
• Page End: A358
• Publication Date: 2001-06-01
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2001.907
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: We have shown that sera from patients with rheumatoid arthritis (RA) contain a variety of autoantibodies to unknown proteins such as 60-, 45-, and 75-kDa proteins, in preliminary immunoblot studies using HeLa cell extracts. 1 By molecular cloning of the target antigens, we have demonstrated that calpastatin (endogenous protein inhibitor of calpain, calcium-dependent cysteine proteinase) is one of such autoantigens and the presence of anti-calpastatin antibodies may be related to pathogenic mechanisms of RA. 2, 3 Objectives: We have attempted to identify autoantigens that were recognised by newly identified autoantibodies discovered in RA patient sera. We hereby describe that human myc far upstream element binding protein (FUSEbp) is a new target of autoantibodies in RA. Methods: Molecular cloning was performed using a lambda gt11 cDNA library constructed from HeLa cell mRNA and RA patient sera that contain autoantibodies to unknown 75-kDa proteins as probes. cDNA inserts of isolated clones were sequenced, and detailed homologies of nucleotide and amino acid sequences were analysed through the BLAST server at NCBI DNA databank. Immunoblot analysis was examined using bacterial lysates prepared from lysogenic E.coli Y1089 carrying the recombinant lambda phages. The partial cDNA (position 192–975 of FUSEbp mRNA, termed FUSEbp-A) was amplified by PCR and ligated into an expression vector (pMAL-C2X). The expressed FUSEbp-A-maltose binding protein fusion protein was analysed by immunoblotting for patient sera. Results: The cDNA (termed RA9–2) expressing the fusion protein recognised by RA probe sera was isolated, and a 1.2 kb insert of RA9–2 was found to show a 99% homology at amino acid level with FUSEbp. The deduced molecular mass of FUSEbp was identical with the size of the 75-kDa protein in HeLa cell extracts. However, this expressed bacterial lysates containing the lambda phage were reactive with only one of 72 RA (1%) and one of 36 SLE (3%) patient sera. In contrast, the FUSEbp-A fusion protein was recognised by 7 of 72 RA sera (10%) as well as the probe serum in immunoblot analysis. Conclusion: Human myc FUSEbp, regulatory factor of c-myc expression, 4 may be a novel autoantigen recognised by sera from patients with RA In RA, synovial fibroblasts exhibit elevated gene expression of proto-oncogenes such as c-myc. Although it remains unclear how autoantibodies to FUSEbp can be associated with etiologic and pathogenic mechanisms in RA, increased expression and release of FUSEbp may induce antoantibodies to FUSEbp in RA-specific synovial proliferation and cartilage destruction. References: Nojima T, et al. Jpn J Rheumatol. 1996;6:189–200 Mimori T, Nojima T, et al. Proc Natl Acad Sci USA 1995;92:7267–71 Kanazawa Y, Nojima T, et al. Modern Rheumatol. 2000;10: 38–44 He L, et al. EMBO J. 2000;19(5):1034–44